Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy

Archives of Pediatrics and Adolescent Medicine

Volumn 160, Issue 8, 2006, Pages 778-787

  Ylitalo, Nathalie ^a   Brogly, Susan ^b   Hughes, Michael D ^a   Nachman, Sharon ^c   Dankner, Wayne ^d   Van Dyke, Russell ^e   Seage III, George R ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; EXPOSURE VARIABLE; FEMALE; FOLLOW UP; HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 33746925182     PISSN: 10724710     EISSN: 10724710     Source Type: Journal    
DOI: 10.1001/archpedi.160.8.778     Document Type: Article

References (34)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Soh C-H, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4T-cell recovery in HIV-1 infected children and adolescents. Lancet. 2003;362:2045-2051.
3. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
4. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
5. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A; Multicenter AIDS Cohort Study. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15:347-355.
6. Cameron DW, Heath-Chiozzi M, Danner S, et al; Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351:543-549.
7. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect. 2001;42:134-139.
8. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
9. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitrabine. N Engl J Med. 1996;334:1011-1017.
10. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998;351:1682-1686.
11. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS. 1997;11:F107-F111.
12. Cohen Stuart JW, Slieker WA, Rijkers GT, et al; Dutch Study Group for Children With HIV Infections. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. AIDS. 1998;12:2155-2159.
13. Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Woerner I, Bab A; Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet. 2000;355:1331-1332.
14. Hainaut M, Ducarme M, Schandene L, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1 infected children. Pediatr Infect Dis J. 2003;22:62-69.
15. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102.
16. O'Brien WA, Hartigan PM, Martin D, et al; Veterans Affairs Cooperative Study Group on AIDS. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426-431.
17. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
18. Mofenson LM, Korelitz J, Meyer WA III, et al; National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175:1029-1038.
19. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761.
20. Dunn D; HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1 infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611.
21. Gortmaker SL, Hughes M, Cervia J, et al; Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
22. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
23. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-10.
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980:22-23, 79-81.
25. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://www.aidsinfo.nih.gov. Accessed November 30, 2004.
26. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM; Pediatric European Network for Treatment of AIDS. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med. 2002;3:215-226.
27. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach: executive summary. http://www.who.int/hiv/pub/guidelines/en. Accessed November 30, 2003.
28. van Rossum A-M, Scherpbier H, van Lochem E, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS. 2001;15:2267-2275.
29. Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915-1924.
30. European Collaborative Study. Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr. 2003;33:635-641.
31. Van Dyke RB, Lee S, Johnson GM, et al; Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:e61.
32. European Collaborative Study. Level and pattern of RNA viral load over age: differences between girls and boys? AIDS. 2002;16:97-104.
33. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with quantitative HIV-1 RNA levels and immunological progression. J Acquir Immune Defic Syndr. 2000;24:218-226.
34. Dankner WM, Lindsey JC, Levin MJ; Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300, and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001;20:40-48.